Search Results - Angel R. Payer

  • Showing 1 - 4 results of 4
Refine Results
  1. 1

    Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia by Mónica Villa-Álvarez, Mónica Villa-Álvarez, Mónica Villa-Álvarez, Christian Sordo-Bahamonde, Christian Sordo-Bahamonde, Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, Seila Lorenzo-Herrero, Seila Lorenzo-Herrero, Ana P. Gonzalez-Rodriguez, Ana P. Gonzalez-Rodriguez, Ana P. Gonzalez-Rodriguez, Angel R. Payer, Angel R. Payer, Angel R. Payer, Esther Gonzalez-Garcia, Esther Gonzalez-Garcia, María C. Villa-Álvarez, Alejandro López-Soto, Alejandro López-Soto, Alejandro López-Soto, Segundo Gonzalez, Segundo Gonzalez, Segundo Gonzalez

    Published in Frontiers in Immunology (2018-12-01)
    Get full text
    Article


  2. 2

    Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial by Ramón García-Sanz, Albert Oriol, María J. Moreno, Javier de la Rubia, Angel R. Payer, Miguel T. Hernández, Luis Palomera, Ana I. Teruel, María J. Blanchard, Mercedes Gironella, Paz Ribas, Joan Bargay, Eugenia Abellá, Miquel Granell, Enrique M. Ocio, Josep M. Ribera, Jesús F. San Miguel, María V. Mateos

    Published in Haematologica (2015-09-01)
    Get full text
    Article


  3. 3

    Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption by Julio Delgado, Itziar Salaverria, Tycho Baumann, Alejandra Martínez-Trillos, Eriong Lee, Laura Jiménez, Alba Navarro, Cristina Royo, Rodrigo Santacruz, Cristina López, Angel R. Payer, Enrique Colado, Marcos González, Lluís Armengol, Dolors Colomer, Magda Pinyol, Neus Villamor, Marta Aymerich, Ana Carrió, Dolors Costa, Guillem Clot, Eva Giné, Armando López-Guillermo, Elías Campo, Sílvia Beà

    Published in Haematologica (2014-11-01)
    Get full text
    Article


  4. 4

    Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia by Neus Giménez, Alejandra Martínez-Trillos, Arnau Montraveta, Mónica Lopez-Guerra, Laia Rosich, Ferran Nadeu, Juan G. Valero, Marta Aymerich, Laura Magnano, Maria Rozman, Estella Matutes, Julio Delgado, Tycho Baumann, Eva Gine, Marcos González, Miguel Alcoceba, M. José Terol, Blanca Navarro, Enrique Colado, Angel R. Payer, Xose S. Puente, Carlos López-Otín, Armando Lopez-Guillermo, Elias Campo, Dolors Colomer, Neus Villamor

    Published in Haematologica (2019-03-01)
    Get full text
    Article


Search Tools: